Download PDF

1. Company Snapshot

1.a. Company Description

Champions Oncology, Inc.develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States.Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.


The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process.The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis.


The company markets its products through internet, word of mouth, and sales force to patients and physicians.The company was formerly known as Champions Biotechnology, Inc.and changed its name to Champions Oncology, Inc.


in April 2011.Champions Oncology, Inc.was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Show Full description

1.b. Last Insights on CSBR

Champions Oncology's recent performance was driven by strong revenue growth, with Q2 2025 revenue increasing 17% to $13.5 million and Q3 2025 revenue expected to be reported after market close on March 11, 2025. The company's gross margin expanded to 45% in Q2, and adjusted EBITDA reached $1.1 million. Champions also enhanced its clinical bioanalytical services portfolio with new technology and leadership, and announced 17 abstracts accepted for presentation at the 2025 American Association for Cancer Research Annual Meeting. The company's operating efficiencies and growth strategy have positioned it for continued sales growth, with a 10% CAGR expected to 2026.

1.c. Company Highlights

2. Champions Oncology Q3 FY26: Strong Momentum Amid Resilient Services

Champions Oncology reported a solid third quarter for fiscal 2026, posting total revenue of $16.6 million—down 3% YoY due to a large data deal closed last year—but core study revenue hit a record $16.6 million, up 32% year‑over‑year. Adjusted EBITDA rose to $575 k, a turnaround from the prior quarter’s GAAP loss of $275 k, and the company remains on track for a full‑year positive adjusted EBITDA. Gross margin held at 47%, supported by a gradual shift of outsourced lab work back in‑house. Operating expenses climbed to $7.2 million, reflecting strategic investments in the data platform and commercial expansion. The company closed the quarter with $7.1 million in cash and no debt. <cite>“The data platform is a key differentiator and we see bookings converting as customer budgets stabilize,” said the CFO during the call.</cite> Valuation-wise, Champions trades at a P/S of 1.38 and an EV/EBITDA of –86.55, reflecting the company’s negative EBITDA but strong growth prospects.

Publication Date: Apr -13

📋 Highlights
  • Record Services Revenue & EBITDA:: Achieved $16.6M core study revenue (32% YoY growth), with third consecutive positive adjusted EBITDA of $575K.
  • Revenue Shift Impact:: Total revenue $16.6M (-3% YoY) due to prior-year data deal, but 6-figure data deal expected to boost Q4 revenue.
  • Margin & Costs:: Gross margin 47% (impacted by outsourced labs), operating expenses $7.2M (investing in data platform and commercial team).
  • Cash Position:: Ended quarter with $7.1M in cash and no debt, supporting growth initiatives and Corellia funding.
  • Corellia Outlook:: Subsidiary in VC and licensing talks; external funding could redirect EBITDA investments to other growth areas.

Record Services Revenue Fuels Growth

The core translational oncology services platform delivered a record $16.6 million in revenue, driven by the PDX Bank’s market differentiation and a stable customer base. Bookings are translating into revenue as budgets normalize, setting the stage for the projected 11.5% revenue growth next year.

Margins Under Pressure but Improving

Gross margin of 47% was impacted by outsourced laboratory work, yet the company expects in‑house production to lift margins in FY27. Operating expenses rose to $7.2 million, but the spend is earmarked for high‑impact initiatives such as the data platform and commercial team expansion.

Cash Position and Debt Profile

With $7.1 million in cash and zero debt, Champions maintains a clean balance sheet, allowing flexibility to fund Corellia’s discovery therapeutics and other strategic initiatives without external financing.

Strategic Focus for FY27 and Beyond

The company’s focus remains on execution, revenue growth, margin improvement, and investment in strategic capabilities. Expected returns from these investments are projected to materialize in FY27, with a more pronounced acceleration anticipated in FY28.

Corellia’s Growth Potential

Corellia, the wholly owned discovery subsidiary, continues to generate attractive data and is in talks with potential venture capital partners. Funding of Corellia is included in FY27 budgeting, but an external round could reallocate the current EBITDA investment toward other growth initiatives.

3. NewsRoom

Card image cap

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Apr -09

Source: accessnewswire.com

Card image cap

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Mar -30

Source: accessnewswire.com

Card image cap

Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript

Mar -12

Source: seekingalpha.com

Card image cap

Champions Oncology Reports Revenue of $16.6 Million

Mar -12

Source: accessnewswire.com

Card image cap

Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026

Mar -05

Source: accessnewswire.com

Card image cap

Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript

Dec -15

Source: seekingalpha.com

Card image cap

Market Today: Ford axes Lightning, iRobot bankrupt, Nvidia-China chips

Dec -15

Source: gurufocus.com

Card image cap

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

Dec -15

Source: accessnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (3.00%)

6. Segments

Pharmacology Services

Expected Growth: 3%

Champions Oncology's Pharmacology Services growth is driven by increasing demand for personalized medicine, advancements in precision oncology, and rising adoption of biomarker-based drug development. Additionally, growing need for targeted therapies, expanding oncology pipeline, and strategic partnerships are contributing to the segment's growth.

Other Translational Oncology Solutions

Expected Growth: 3%

Champions Oncology's Other Translational Oncology Solutions segment growth is driven by increasing adoption of personalized medicine, rising demand for biomarker-based cancer diagnostics, and strategic partnerships with pharmaceutical companies to accelerate drug development. Additionally, advancements in immuno-oncology and targeted therapies are fueling growth in this segment.

Personalized Oncology Services

Expected Growth: 3%

Champions Oncology's Personalized Oncology Services growth is driven by increasing demand for precision medicine, advancements in genomics and immunotherapy, and a growing need for personalized treatment options. Additionally, the company's unique tumorgraft platform and comprehensive biomarker testing capabilities position it for continued growth.

7. Detailed Products

TumorGraft

A platform that develops and banks patient-derived xenograft (PDX) models from various types of cancer, allowing for personalized cancer treatment and research

AngioPred

A predictive analytics platform that uses artificial intelligence and machine learning to identify biomarkers for angiogenesis, a key factor in cancer progression

Champions TumorGraft Platform

A comprehensive platform that provides a suite of services, including PDX model development, biomarker discovery, and personalized medicine solutions

Personalized Oncology Solutions

A range of services that provide personalized cancer treatment plans, including biomarker analysis, genomic profiling, and PDX modeling

8. Champions Oncology, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Champions Oncology, Inc. has a moderate threat of substitutes due to the availability of alternative cancer treatment options, but the company's unique approach to personalized oncology and its strong research and development capabilities mitigate this threat.

Bargaining Power Of Customers

Champions Oncology, Inc. has a low bargaining power of customers due to the specialized nature of its services and the lack of alternative providers, giving the company significant pricing power.

Bargaining Power Of Suppliers

Champions Oncology, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for its research and development activities, but the company's reliance on a few key suppliers for certain materials and services limits its negotiating power.

Threat Of New Entrants

Champions Oncology, Inc. has a low threat of new entrants due to the high barriers to entry in the personalized oncology market, including the need for significant research and development investments and regulatory approvals.

Intensity Of Rivalry

Champions Oncology, Inc. operates in a highly competitive market with several established players, leading to a high intensity of rivalry, but the company's unique approach and strong research and development capabilities help it to differentiate itself from competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 64.97%
Debt Cost 3.95%
Equity Weight 35.03%
Equity Cost 5.92%
WACC 4.64%
Leverage 185.48%

11. Quality Control: Champions Oncology, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Dianthus Therapeutics

A-Score: 4.8/10

Value: 6.7

Growth: 6.0

Quality: 5.0

Yield: 0.0

Momentum: 9.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Tarsus Pharmaceuticals

A-Score: 4.5/10

Value: 6.2

Growth: 3.2

Quality: 4.1

Yield: 0.0

Momentum: 10.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Champions Oncology

A-Score: 4.5/10

Value: 2.2

Growth: 7.0

Quality: 5.9

Yield: 0.0

Momentum: 10.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Kymera Therapeutics

A-Score: 4.1/10

Value: 6.2

Growth: 3.1

Quality: 5.1

Yield: 0.0

Momentum: 8.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Oncternal Therapeutics

A-Score: 3.8/10

Value: 9.0

Growth: 4.3

Quality: 3.3

Yield: 0.0

Momentum: 6.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
TScan Therapeutics

A-Score: 2.9/10

Value: 8.2

Growth: 4.2

Quality: 4.4

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

6.18$

Current Price

6.18$

Potential

-0.00%

Expected Cash-Flows